Biotech Moves to AI-Native Builder Phase

The biotech industry is entering a new "Builder Phase" as drug discovery transitions to AI-native systems ^[1]. According to the 2026 Biotech AI Report from Benchling, organizations are moving beyond pilot programs ^[2]. These companies now focus on fully integrated AI platforms to accelerate research and development ^[1][2]. Scientists are upskilling as "scientific translators" to bridge the gap between biology and machine learning ^[2]. Early adopters of these systems report reaching targets 50% faster by linking AI design with experiments ^[2]. This shift aims to make advanced computational tools a standard part of laboratory workflows ^[1][2]. New partnerships are also expanding access to these powerful tools. Benchling and Lilly TuneLab recently partnered to democratize AI models for scientists everywhere ^[3]. This collaboration reflects a broader industry trend toward scaling AI-driven discovery across various therapeutic areas ^[2][3].